ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

April 6, 2018: By Jon Swedien

ThromboGenicsThromboGenics’ candidate for diabetic macular edema (DME) was safe and well tolerated in a Phase I/II study, the Belgium company announced April 4.

The candidate, THR-317 (anti-PlGF), is a recombinant humanized monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF), ThromboGenics said.

In preclinical models, anti-PlGF has been shown to be anti-inflammatory, in addition to anti-angiogenic and anti-edema, the company said.

The study enrolled 49 patients and included anti-VEGF naïve patients as well as sub-optimal anti-VEGF responders, ThromboGenics said.

Thirty percent of the anti-VEGF treatment naïve study subjects treated with THR-317 in the 8 mg group showed a greater than 15-letter gain from baseline at day 90 compared with 5.3 percent in the 4 mg group, the company said.

ThromboGenics said the data support a next study evaluating THR-317 in combination with an anti- VEGF, and the company hopes to initiate a clinical trial in Q2-2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023